Evidence map›Paper›PMID 41390356›Full record

ArticleScientific reports2025

Further characterisation of immortalised human lymphatic endothelial cells to explore their transcriptomic profile and VEGFC response.

Kazim Ogmen, Ruby Moy, Sara E Dobbins, Lotte van den Bent, Onno Kranenburg, Jeroen Hagendoorn, Alan Pittman, Pia Ostergaard, Silvia Martin-Almedina

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazim OgmenSchool of Health & Medical Sciences, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.
Ruby MoySchool of Health & Medical Sciences, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.
Sara E DobbinsSchool of Health & Medical Sciences, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.
Lotte van den BentLaboratory of Translational Oncology & Dept. of Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Onno KranenburgLaboratory of Translational Oncology & Dept. of Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Jeroen HagendoornLaboratory of Translational Oncology & Dept. of Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Alan PittmanSchool of Health & Medical Sciences, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.
Pia Ostergaard *School of Health & Medical Sciences, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.
Silvia Martin-Almedina *School of Health & Medical Sciences, City St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK. smartina@citystgeorges.ac.uk.ORCID 0000-0001-5282-6662

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vitro modelling relies on the availability of suitable cell types that accurately represent the organs under study. In lymphatic research, human dermal lymphatic endothelial cells represent the "gold standard", even though they lose their identity and proliferative capacity over time. A recently established immortalised lymphatic endothelial cell line (imLEC) could become a promising new tool for lymphatic disease modelling. We further characterised this cell line by comparing imLECs and HDLECs in terms of the expression of proteins essential for correct lymphatic function, and the proliferation, migration and sprouting responses to vascular endothelial growth factor C (VEGFC). We show similarities in the expression of lymphatic markers and VEGFC-driven cellular responses, supporting imLECs can retain their VEGFC-driven lymphangiogenic capacity without losing their lymphatic identity. RNA sequencing, however, revealed certain transcriptional differences in genes regulating lymphatic function in health and disease, highlighting the need for further validation at single gene level or specific lymphatic-associated signalling pathways. We acknowledge these limitations should be considered in future applications. Nonetheless, we believe that imLECs represent a useful model for the development of gene editing techniques allowing better modelling of lymphatic disease-associated genetic variants, ensuring long-term culture and providing higher reproducibility in genotype-phenotype validation analyses.

Indexed as

Endothelial CellsTranscriptomeVascular Endothelial Growth Factor CCell LineCell MovementCell ProliferationGene Expression ProfilingHumansLymphangiogenesisLymphatic VesselsVascular Endothelial Growth Factor CVEGFC protein, human

Identifiers

PMID41390356
PMCPMC12756254

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.